Concord Biotech share news and announcements
NSE: CONCORDBIOBSE: 543960Pharmaceuticals & BiotechnologySmall Cap
Last close ₹1,229.30down ₹41.40 (3.26%)BSE ₹1,228.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,270.70.
52-week range of traded prices to 23 Oct 2026
₹987.00Low, 2 Apr 2026₹1,615.00High, 20 Aug 2026
- Next results date: the board meets on 27 Oct 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12,860 Cr496th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 46.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.61%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 14.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 15.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 96,70653.4% delivered
Concord Biotech share news and announcements
151 announcements, routine notices left out, newest first. Page 3 of 4.
Sep 2024
24 Sep · Analysts
24 Sep · Legal
The exchange asked on 23 Sep 2024
12 Sep · Analysts
12 Sep · Analysts
Aug 2024
30 Aug · Analysts
22 Aug · Updates
9 Aug · Board meeting
7 Aug · Analysts
Jul 2024
Jun 2024
4 Jun · Analysts
May 2024
23 May · Management
23 May · Corporate action
21 May · Analysts
Apr 2024
12 Apr · Legal
Significant increase in volume has been observed in Concord Biotech Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Mar 2024
Feb 2024
13 Feb · Analysts
8 Feb · Board meeting
Jan 2024
31 Jan · Analysts
Dec 2023
14 Dec · Analysts
Nov 2023
20 Nov · Analysts
8 Nov · Board meeting
Oct 2023
31 Oct · Analysts
11 Oct · Trading Plan under PIT
Sep 2023
30 Sep · Management
6 Sep · Board meeting
1 Sep · Analysts
Aug 2023
25 Aug · Management